In particular, a CXCR2 antagonist may be useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) that are associated with a high tissue burden of activated neutrophils. This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.